Trial · NCT04564742
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | The hierachical composite endpoint of all components | 1990 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | The hierachical composite endpoint of all components | 1970 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | Death, adjudicated | 41 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | Death, adjudicated | 33 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | Hospitalisation due to HF | 32 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | Hospitalisation due to HF | 41 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | Non-fatal MI | 29 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | Non-fatal MI | 32 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | AF/Flutter event | 8 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | AF/Flutter event | 15 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | New onset of T2DM | 40 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | New onset of T2DM | 74 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | NYHA Classification at last visit, measuring limitations of physical activity | 1839 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | NYHA Classification at last visit, measuring limitations of physical activity | 1773 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Dapa 10 mg | Body Weight decrease of at least 5% at last visit | 684 | Participants | |
| Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) | Placebo | Body Weight decrease of at least 5% at last visit | 468 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04564742/results